Compare Nebius Group NV (NBIS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs GeneDx Holdings Corp — how do they compare? Nebius Group NV trades at $221.55 (market cap $59.73B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nebius Group NV is far larger — about 29.6× GeneDx Holdings Corp's market cap, and Nebius Group NV is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and GeneDx Holdings Corp for 19 Days on average.
| NBIS | WGS | |
|---|---|---|
Market Cap | $59.73B | $2.02B |
Volume | 21,563,700 | 734,640 |
Sector | Technology | Health |
52-Week High | $286.69 | $167.51 |
52-Week Low | $73.87 | $34.51 |
Typical Hold Time | 24 Days | 19 Days |
Enterprise Value | $61.86B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $221.12, down 6.73% over 24 hours amid a bearish technical signal. The stock shows strong analyst support with an 81.82% buy rating and a $288.67 consensus price target, but faces high valuations with a P/E of 845.04 and negative earnings in recent quarters. Recent news highlights AI infrastructure growth potential, including a $37 billion backlog and strategic acquisitions like Inferize, though insider selling and competitive pressures pose concerns.
The outlook for NBIS hinges on executing its AI cloud expansion, with revenue projected to surge from $530 million in 2025 to $1.4 billion in 2026. Risks include elevated debt from aggressive investing, negative net income margins, and potential AI market volatility. The stock offers upside if growth targets are met but remains sensitive to sector sentiment and financing stability.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
